{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T14:02:41Z","timestamp":1776261761895,"version":"3.50.1"},"reference-count":51,"publisher":"Japanese Society of Internal Medicine","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2019,2,15]]},"DOI":"10.2169\/internalmedicine.0891-18","type":"journal-article","created":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T18:30:09Z","timestamp":1539714609000},"page":"497-504","source":"Crossref","is-referenced-by-count":4,"title":["Association of Papillary Thyroid Carcinoma with Primary Aldosteronism"],"prefix":"10.2169","volume":"58","author":[{"given":"Shigenori","family":"Nakamura","sequence":"first","affiliation":[{"name":"Thyroid and Diabetic Division, Department of Internal Medicine, Japanese Red Cross Gifu Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatoshi","family":"Ishimori","sequence":"additional","affiliation":[{"name":"Thyroid and Diabetic Division, Department of Internal Medicine, Japanese Red Cross Gifu Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriyoshi","family":"Yamakita","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Matsunami General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Shimamoto K, Ando K, Fujita T, et al. The Japanese society of hypertension guidelines for the management of hypertension (JSH 2014). Hypertens Res 37: 253-392, 2014.","DOI":"10.1038\/hr.2014.20"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Omura M, Saito J, Yamaguchi K, Kakuta Y, Nishikawa T. Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res 27: 193-202, 2004.","DOI":"10.1291\/hypres.27.193"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Miyake Y, Tanaka K, Nishikawa T, et al. Prognosis of primary aldosteronism in Japan: results from a nationwide epidemiological study. Endocr J 61: 35-40, 2014.","DOI":"10.1507\/endocrj.EJ13-0353"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 101: 1889-1916, 2016.","DOI":"10.1210\/jc.2015-4061"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Armanini D, Nacamulli D, Scaroni C, et al. High prevalence of thyroid ultrasonographic abnormalities in primary aldosteronism. Endocrine 22: 155-159, 2003.","DOI":"10.1385\/ENDO:22:2:155"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Turchi F, Ronconi V, di Tizio V, Boscaro M, Giacchetti G. Blood pressure, thyroid-stimulating hormone, and thyroid disease prevalence in primary aldosteronism and essential hypertension. Am J Hypertens 24: 1274-1279, 2011.","DOI":"10.1038\/ajh.2011.144"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Lang K, Weber K, Quinkler M, et al. Prevalence of malignancies in patients with primary aldosteronism. J Clin Endocrinol Metab 101: 1656-1663, 2016.","DOI":"10.1210\/jc.2015-3405"},{"key":"8","unstructured":"8. Nakamura S. Primary aldosteronism in patients with thyroid diseases. Medical Journal of Japanese Red Cross Gifu Hospital 26: 3-8, 2014 (in Japanese)."},{"key":"9","unstructured":"9. M\u00e9deau V, Moreau F, Trinquart L, et al. Clinical and biochemical characteristics of normotensive patients with primary aldosteronism: a comparison with hypertensive cases. Clin Endocrinol (Oxf) 69: 20-28, 2008."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Ito Y, Takeda R, Takeda Y. Subclinical primary aldosteronism. Best Pract Res Clin Endocrinol Metab 26: 485-495, 2012.","DOI":"10.1016\/j.beem.2011.11.006"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Nishikawa T, Omura M, Satoh F, et al. Guidelines for the diagnosis and treatment of primary aldosteronism - The Japan Endocrine Society 2009 - . Endocr J 58: 711-721, 2011.","DOI":"10.1507\/endocrj.EJ11-0133"},{"key":"12","unstructured":"12. Consensus Statement on the Clinical Practice of Primary Aldosteronism in Japan-Jaoan Endocrine Society. Folia Endocrinol Jap 92 (Suppl): 1-49, 2016 (in Japanese)."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Queisser N, Oteiza PI, Stopper H, Oli RG, Schupp N. Aldosterone induces oxidative stress, oxidative DNA damage and NF-\u03baB-activation in kidney tubule cells. Mol Carcinog 50: 123-135, 2011.","DOI":"10.1002\/mc.20710"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Queisser N, Happ K, Link S, et al. Aldosterone induces fibrosis, oxidative stress and DNA damage in livers of male rats independent of blood pressure changes. Toxicol Appl Pharmacol 280: 399-407, 2014.","DOI":"10.1016\/j.taap.2014.08.029"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. King S, Bray S, Galbraith S, Christie L, Fleming S. Evidence for aldosterone-dependent growth of renal cell carcinoma. Int J Exp Pathol 95: 244-250, 2014.","DOI":"10.1111\/iep.12074"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Kaji K, Yoshiji H, Kitade M, et al. Selective aldosterone blocker, eplerenone, attenuates hepatocellular carcinoma growth and angiogenesis in mice. Hepatol Res 40: 540-549, 2010.","DOI":"10.1111\/j.1872-034X.2010.00636.x"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Krysiak R, Okopien B. Coexistence of primary aldosteronism and Hashimoto's thyroiditis. Rheumatol Int 32: 2561-2563, 2012.","DOI":"10.1007\/s00296-011-2032-6"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Santori C, Di Veroli C, Di Lazzaro F, et al. High prevalence of thyroid disfunction in primary hyperaldosteronism. Recenti Prog Med 96: 352-356, 2005 (in Italian, Abstract in English).","DOI":"10.1701\/53.543"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Greenman Y, Trostanetsky Y, Ben-Shemen S, et al. Thyroid cysts: a new extra-adrenal site of aldosterone synthase expression and increased aldosterone content. Clin Endocrinol (Oxf) 66: 886-889, 2007.","DOI":"10.1111\/j.1365-2265.2007.02828.x"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Tanabe A, Naruse M, Takagi S, et al. Variability in the renin\/aldosterone profile under random and standardized sampling conditions in primary aldosteronism. J Clin Endocrinol Metab 88: 2489-2494, 2003.","DOI":"10.1210\/jc.2002-021476"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Ito Y, Takeda R, Karashima S, Yamamoto Y, Yoneda T, Takeda Y. Prevalence of primary aldosteronism among prehypertensive and stage 1 hypertensive subjects. Hypertens Res 34: 98-102, 2011.","DOI":"10.1038\/hr.2010.166"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Khan S, Duan P, Yao L, Hou H. Shiftwork-mediated disruptions of circadian rhythms and sleep homeostasis cause serious health problems. Int J Genomics 2018: 8576890, 2018.","DOI":"10.1155\/2018\/8576890"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Doi M, Takahasi Y, Komatsu R, et al. Salt-sensitive hypertension in circadian clock-deficient Cry-null mice involves dysregulated adrenal Hsd3b6. Nat Med 16: 67-74, 2010.","DOI":"10.1038\/nm.2061"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Rahman A, Hasan AU, Nishiyama A, Kobori H. Altered circadian timing system-mediated non-dipping pattern of blood pressure and associated cardiovascular disorders in metabolic and kidney diseases. Int J Mol Sci 19: E400, 2018.","DOI":"10.3390\/ijms19020400"},{"key":"25","doi-asserted-by":"publisher","unstructured":"25. Turek FW, Joshu C, Kohsaka A, et al. Obesity and metabolic syndrome in circadian clock mutant mice. Science 308: 1043-1045, 2005.","DOI":"10.1126\/science.1108750"},{"key":"26","doi-asserted-by":"publisher","unstructured":"26. Marcheva B, Ramsey KM, Buhr ED, et al. Disruption of the clock components CLOCK and BMAL1 leads to hypoinsulinemia and diabetes. Nature 466: 627-631, 2010.","DOI":"10.1038\/nature09253"},{"key":"27","doi-asserted-by":"publisher","unstructured":"27. Fu L, Pelicano H, Liu J, Huang P, Lee C. The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell 111: 41-50, 2002.","DOI":"10.1016\/S0092-8674(02)00961-3"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Mannic T, Meyer P, Triponez F, et al. Circadian clock characteristics are altered in human thyroid malignant nodules. J Clin Endocrinol Metab 98: 4446-4456, 2013.","DOI":"10.1210\/jc.2013-2568"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Doi M. Circadian clock-deficient mice as a tool for exploring disease etiology. Biol Pharm Bull 35: 1385-1391, 2012.","DOI":"10.1248\/bpb.b12-00364"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Okamura H, Doi M, Goto K, Kojima R. Clock genes and salt-sensitive hypertension: a new type of aldosterone-synthesizing enzyme controlled by the circadian clock and angiotensin II. Hypertens Res 39: 681-687, 2016.","DOI":"10.1038\/hr.2016.91"},{"key":"31","doi-asserted-by":"publisher","unstructured":"31. Sabbadin C, Mian C, Nacamulli D, et al. Association of primary aldosteronism with chronic thyroiditis. Endocrine 55: 303-306, 2017.","DOI":"10.1007\/s12020-016-0880-2"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Shi Y, Wang H, Su Z, et al. Differentiation imbalance of Th1\/Th17 in peripheral blood mononuclear cells might contribute to pathogenesis of Hashimoto's thyroiditis. Scand J Immunol 72: 250-255, 2010.","DOI":"10.1111\/j.1365-3083.2010.02425.x"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Herrada AA, Contreras FJ, Marini NP, et al. Aldosterone promotes autoimmune damage by enhancing Th17-mediated immunity. J Immunol 184: 191-201, 2010.","DOI":"10.4049\/jimmunol.0802886"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Herrada AA, Campino C, Amador CA, Michea LF, Fardella CE, Kalergis AM. Aldostetrone as a modulater of immunity: implications in the organ damage. J Hypertens 29: 1684-1692, 2011.","DOI":"10.1097\/HJH.0b013e32834a4c75"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Boi F, Lai ML, Marziani B, Minerba L, Faa G, Mariotti S. High prevalence of suspicious cytology in thyroid nodules associated with positive thyroid autoantibodies. Eur J Endocrinol 153: 637-642, 2005.","DOI":"10.1530\/eje.1.02020"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Spencer CA. Clinical utility of thyroglobulin antibody (TgAb) measurements for patients with differentiated thyroid cancers (DTC). J Clin Endocrinol Metab 96: 3615-3627, 2011.","DOI":"10.1210\/jc.2011-1740"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Paparodis R, Imam S, Todorova-Koteva K, Staii A, Jaume JC. Hashimoto's thyroiditis pathology and risk for thyroid cancer. Thyroid 24: 1107-1114, 2014.","DOI":"10.1089\/thy.2013.0588"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Matsuki K, Hathaway CK, Chang AS, Smithies O, Kakoki M. Transforming growth factor beta1 and aldosterone. Curr Opin Nephrol Hypertens 24: 139-144, 2015.","DOI":"10.1097\/MNH.0000000000000100"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. \u0160oml\u00f3ov\u00e1 Z, Petr\u00e1k O, Rosa J, et al. Inflammatory markers in primary aldosteronism. Physiol Res 65: 229-237, 2016.","DOI":"10.33549\/physiolres.932994"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Petramala L, Iacobellis G, Carnevale R, et al. Enhanced soluble serum CD40L and serum P-selectin levels in primary aldosteronism. Horm Metab Res 48: 440-445, 2016.","DOI":"10.1055\/s-0042-103588"},{"key":"41","doi-asserted-by":"publisher","unstructured":"41. Rezzonico J, Rezzonico M, Pusiol E, Pitoia F, Niepomniszcze H. Introducing the thyroid gland as another victim of the insulin resistance syndrome. Thyroid 18: 461-464, 2008.","DOI":"10.1089\/thy.2007.0223"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Ayturk S, Gursoy A, Kut A, Anil C, Nar A, Tutuncu NB. Metabolic syndrome and its components are associated with increased thyroid volume and nodule prevalence in a mild-to-moderate iodine-deficient area. Eur J Endocrinol 161: 599-605, 2009.","DOI":"10.1530\/EJE-09-0410"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Min SH, Kim SH, Jeong IK, et al. Independent association of serum aldosterone level with metabolic syndrome and insulin resistance in Korean adults. Korean Circ J 48: 198-208, 2018.","DOI":"10.4070\/kcj.2017.0200"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Hannemann A, Meisinger C, Bidlingmaier M, et al. Association of plasma aldosterone with the metabolic syndrome in two German populations. Eur J Endocrinol 164: 751-758, 2011.","DOI":"10.1530\/EJE-10-1074"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Catena C, Lapenna R, Baroselli S, et al. Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J Clin Endocrinol Metab 91: 3457-3463, 2006.","DOI":"10.1210\/jc.2006-0736"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Fallo F, Della Mea P, Sonino N, et al. Adiponectin and insulin sensitivity in primary aldosteronism. Am J Hypertens 20: 855-861, 2007.","DOI":"10.1016\/j.amjhyper.2007.03.012"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Fallo F, Veglio F, Bertello C, et al. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab 91: 454-459, 2006.","DOI":"10.1210\/jc.2005-1733"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Rezz\u00f3nico JN, Rezz\u00f3nico M, Pusiol E, Pitoia F, Niepomniszcze H. Increased prevalence of insulin resistance in patients with differentiated thyroid carcinoma. Metab Syndr Relat Disord 7: 375-380, 2009.","DOI":"10.1089\/met.2008.0062"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Vella V, Sciacca L, Pandini G, et al. The IGF system in thyroid cancer: new concepts. Mol Pathol 54: 121-124, 2001.","DOI":"10.1136\/mp.54.3.121"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Nishikawa M, Inada M, Kurata S, et al. Primary aldosteronism associated with a primary double cancer of the thyroid and rectum: report of a case. Endocrinol Jpn 28: 735-739, 1981.","DOI":"10.1507\/endocrj1954.28.735"},{"key":"51","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.4081\/rt.2011.e45","volume":"3","author":"SM Wanta","year":"2011","unstructured":"51. Wanta SM, Basina M, Chang SD, et al. A rare case of an aldosterone secreting metastatic adrenocortical carcinoma and papillary thyroid carcinoma in a 31-year-old male. Rare Tumors 3: e45, 2011.","journal-title":"Rare Tumors","ISSN":"https:\/\/id.crossref.org\/issn\/2036-3605","issn-type":"print"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/4\/58_0891-18\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T20:20:18Z","timestamp":1775247618000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/4\/58_0891-18\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,15]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.0891-18","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,15]]}}}